Operates a Contract Research, Development and Manufacturing Organization (CRDMO) that handles outsourced chemistry work for global pharma clients, alongside a smaller Speciality Ingredients business. CRDMO is the dominant earner at Rs 1,772.768 cr (83.5% of segment revenue) with segment EBIT of Rs 1,132.985 cr, covering custom synthesis, fermentation, and process development for both large-pharma and biotech customers, including molecules in late-phase clinical development. Speciality Ingredients contributed Rs 351.565 cr (16.5%) and Rs 179.065 cr in EBIT, supplying ingredients into food, nutraceutical and related end-markets. Total FY26 revenue stood at Rs 2,124.333 cr with a 45.4% EBITDA margin. The biggest input cost is raw materials at 33.6% of revenue, followed by employee cost at 13.3% and other operating expenses at 9.2%. Operations run across 3 plants with 2,282 permanent employees, and the company exports about 85% of its output. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. CRDMO (84%), Speciality Ingredients (17%). Asset-heavy CRDMO with a smaller specialty ingredients tail; export-skewed and net-cash positive.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 2,124 |
| EBITDA (ex other income) | 809 |
| margin % | 38.1 |
| Owners' profit | 592 |
| EPS, as reported (₹) | 0.00 |
| ROE % · ROCE % | 19.5 · 26.8 |
| Debt / equity (x) | 0.02 |
| Cash from operations | 844 |
| Capex | (211) |
| ₹ crore | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue | 540 | 550 | 423 | 611 | 418 |
| Profit before tax | 186 | 230 | 130 | 278 | 145 |
| Net profit | 136 | 173 | 93 | 190 | 120 |
| EPS (₹) | 2.43 | 3.09 | 1.65 | 0.00 | 2.13 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| CRDMO | 1,312 | 82.8 |
| Speciality Ingredients | 272 | 17.2 |
| Total, before eliminations | 1,584 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| ANTHEM BIOSCIENCES LTD ◆ | 52,995 | 136.9 | 17.42 | 54.7 | 19.5 | 26.6 | — | 42.0 |
| ADVANCED ENZYME TECH LTD | 3,286 | 19.8 | 1.95 | 11.6 | 10.3 | 13.4 | 8.2 | 33.7 |
| CCME GLOBAL LIMITED | 136 | 60.0 | 3.39 | — | (1.8) | (1.8) | — | — |
| VIVO BIO TECH LTD. |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · Upside sharing arrangement settled - INR 1,276.83 million paid to founders | business updates | high | — | — |
| 8 Sept 2026 · Settlement of Upside Sharing Arrangement completed | strategic transactions | high | — | — |
| 27 Jul 2026 · Q1 FY27 call: Rs 418 cr revenue, soft quarter on delivery timing shifts | investor communications | medium | — | — |
| 24 Jul 2026 · AGM voting results: all 8 resolutions passed at 20th AGM | board shareholder meetings | low | — | — |
| 22 Jul 2026 · 20th AGM of Anthem Biosciences held on July 22, 2026; all resolutions passed | board shareholder meetings | low | — | — |
| 22 Jul 2026 · Audio recording of Q1 FY27 earnings call available on website | investor communications | low | — | — |
| 22 Jul 2026 · Newspaper ad of Q1 FY27 unaudited results filed with exchanges | compliance | minimal | — | — |
| 21 Jul 2026 · Anthem Biosciences Q1FY27: Revenue falls 22.6% YoY to Rs 4,182 Cr | results | high | — | — |
| 21 Jul 2026 · Anthem Biosciences files revised Q1FY27 earnings presentation | investor communications | medium | — | — |
| 21 Jul 2026 · Q1FY27: Revenue Rs 4,182 Mn, PAT Rs 1,199 Mn; YoY Decline on Delivery Timing | compliance | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 39 |
| 4.1 |
| 0.41 |
| 4.9 |
| (1.8) |
| 3.2 |
| 0.6 |
| 31.5 |
| Shree Ganesh Biotech (India) L | 20 | 24.5 | 0.31 | — | 0.6 | 0.8 | — | (7.0) |
| GENOMIC VALLEY BIOTECH LIMITED | 10 | 262.5 | 2.45 | — | 0.8 | 1.0 | — | 40.5 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 136.9 | 28.9 | 168 of 175 | 4% |
| P/B | 17.4 | 3.3 | 162 of 169 | 4% |
| ROCE | 26.6 | 10.7 | 14 of 189 | 93% |
| ROE | 19.4 | 9.9 | 22 of 177 | 88% |
| Debt / Equity | 0.0 | 0.1 | 60 of 177 | 67% |
| EBITDA margin | 42.0 | 17.7 | 8 of 170 | 96% |
| Revenue growth | (22.6) | 15.3 | 144 of 166 | 13% |
| Profit growth | (11.7) | 30.0 | 115 of 164 | 30% |
| Market cap | 52995 | 803 | 15 of 188 | 93% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
